Phase I trial of N-(phosphonacetyl)-L-aspartic acid (PALA)

T. J. Ervin; R. H. Blum; M. W. Meshad; D. W. Kufe; R. K. Johnson; G. P. Canellos

Phase I trial of N-(phosphonacetyl)-L-aspartic acid (PALA)

T. J. Ervin
, R. H. Blum
, M. W. Meshad
, D. W. Kufe
, R. K. Johnson
, G. P. Canellos

Research output: Contribution to journal › Article › peer-review

17 Scopus citations

Abstract

N-(Phosphonacetyl)-L-aspartic acid (PALA) was given as a 5-day continuous infusion in a phase I trial. Dose-limiting toxic effects noted were diarrhea occurring at doses of ≥ 6 g/m ²/course, mucositis occurring at doses of ≥ 7.5 g/m ²/course, and skin rash occurring at doses > 9 g/m ²/course. No significant CNS, hemorrhagic, gastrointestinal, or hematologic toxicity was noted. In patients with measurable tumor volume, no significant antitumor responses were seen. A dose of 9 g/m ²/course is recommended for a phase II trial.

Original language	English
Pages (from-to)	1067-1071
Number of pages	5
Journal	Cancer Treatment Reports
Volume	64
Issue number	10-11
State	Published - 1980
Externally published	Yes

Cite this

@article{16c4d50bf9f0439a845e89346b797cd3,

title = "Phase I trial of N-(phosphonacetyl)-L-aspartic acid (PALA)",

abstract = "N-(Phosphonacetyl)-L-aspartic acid (PALA) was given as a 5-day continuous infusion in a phase I trial. Dose-limiting toxic effects noted were diarrhea occurring at doses of ≥ 6 g/m 2/course, mucositis occurring at doses of ≥ 7.5 g/m 2/course, and skin rash occurring at doses > 9 g/m 2/course. No significant CNS, hemorrhagic, gastrointestinal, or hematologic toxicity was noted. In patients with measurable tumor volume, no significant antitumor responses were seen. A dose of 9 g/m 2/course is recommended for a phase II trial.",

author = "Ervin, \{T. J.\} and Blum, \{R. H.\} and Meshad, \{M. W.\} and Kufe, \{D. W.\} and Johnson, \{R. K.\} and Canellos, \{G. P.\}",

year = "1980",

language = "English",

volume = "64",

pages = "1067--1071",

journal = "Cancer Treatment Reports",

issn = "0361-5960",

publisher = "Oxford University Press",

number = "10-11",

}

TY - JOUR

T1 - Phase I trial of N-(phosphonacetyl)-L-aspartic acid (PALA)

AU - Ervin, T. J.

AU - Blum, R. H.

AU - Meshad, M. W.

AU - Kufe, D. W.

AU - Johnson, R. K.

AU - Canellos, G. P.

PY - 1980

Y1 - 1980

N2 - N-(Phosphonacetyl)-L-aspartic acid (PALA) was given as a 5-day continuous infusion in a phase I trial. Dose-limiting toxic effects noted were diarrhea occurring at doses of ≥ 6 g/m 2/course, mucositis occurring at doses of ≥ 7.5 g/m 2/course, and skin rash occurring at doses > 9 g/m 2/course. No significant CNS, hemorrhagic, gastrointestinal, or hematologic toxicity was noted. In patients with measurable tumor volume, no significant antitumor responses were seen. A dose of 9 g/m 2/course is recommended for a phase II trial.

AB - N-(Phosphonacetyl)-L-aspartic acid (PALA) was given as a 5-day continuous infusion in a phase I trial. Dose-limiting toxic effects noted were diarrhea occurring at doses of ≥ 6 g/m 2/course, mucositis occurring at doses of ≥ 7.5 g/m 2/course, and skin rash occurring at doses > 9 g/m 2/course. No significant CNS, hemorrhagic, gastrointestinal, or hematologic toxicity was noted. In patients with measurable tumor volume, no significant antitumor responses were seen. A dose of 9 g/m 2/course is recommended for a phase II trial.

UR - https://www.scopus.com/pages/publications/0019273061

M3 - Article

C2 - 7459892

AN - SCOPUS:0019273061

SN - 0361-5960

VL - 64

SP - 1067

EP - 1071

JO - Cancer Treatment Reports

JF - Cancer Treatment Reports

IS - 10-11

ER -

Phase I trial of N-(phosphonacetyl)-L-aspartic acid (PALA)

Abstract

Fingerprint

Cite this